Bristol Myers Squibb Announces Second NVIDIA DGX SuperPOD Deployment

Bristol Myers Squibb (BMS) is deploying its second NVIDIA DGX SuperPOD, marking one of the largest AI clusters in the life sciences sector. This announcement highlights BMS’s commitment to leveraging advanced AI computing infrastructure to enhance its pharmaceutical research capabilities. Erin Davis described the initiative as a step towards creating a ‘SuperDuperPOD’ for optimized AI workloads. This follows BMS’s ongoing investment in AI technologies, which aligns with industry trends towards more powerful computing resources for drug discovery and development. The deployment of the NVIDIA DGX SuperPOD will enable BMS to accelerate its AI-driven projects significantly, impacting its research timelines and operational efficiency. For further details, see the NVIDIA Blog.